Bangladéš - angličtina - DGDA (Directorate General of Drug Administration)

the homoeo research laboratory (bd) ltd. - azadirachta indica - liquid

Bangladéš - angličtina - DGDA (Directorate General of Drug Administration)

zoha homoeo pharmaceutical laboratories - azadirachta indica - liquid

Spojené štáty - angličtina - NLM (National Library of Medicine)

janssen pharmaceuticals, inc. - galantamine hydrobromide (unii: mj4ptd2vvw) (galantamine - unii:0d3q044kca) - galantamine 8 mg - razadyne er is indicated for the treatment of mild to moderate dementia of the alzheimer's type. razadyne er is contraindicated in patients with known hypersensitivity to galantamine hydrobromide or to any excipients used in the formulation. risk summary there are no adequate data on the developmental risk associated with the use of razadyne er or galantamine tablets in pregnant women. in studies conducted in animals, administration of galantamine during pregnancy resulted in developmental toxicity (increased incidence of morphological abnormalities and decreased growth in offspring) at doses similar to or greater than those used clinically (see data). in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data animal data in rats, administration of galantamine (oral doses of 2, 8, or 16 mg/kg/da

Malajzia - angličtina - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

amipro sdn. bhd. - azadirachta indica; cichorium intybus; glycyrrhiza glabra; piper nigrum -

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

glaxo laboratories limited - fazadinium bromide -

Európska únia - angličtina - EMA (European Medicines Agency)

ipsen pharma - mecasermin - laron syndrome - pituitary and hypothalamic hormones and analogues - for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like-growth-factor-1 deficiency (primary igfd).severe primary igfd is defined by:height standard deviation score ≤ -3.0 and;basal insulin-like growth factor-1 (igf-1) levels below the 2.5th percentile for age and gender and;growth hormone (gh) sufficiency;exclusion of secondary forms of igf-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.severe primary igfd includes patients with mutations in the gh receptor (ghr), post-ghr signalling pathway, and igf-1 gene defects; they are not gh deficient, and therefore, they cannot be expected to respond adequately to exogenous gh treatment. it is recommended to confirm the diagnosis by conducting an igf-1 generation test.

Spojené štáty - angličtina - NLM (National Library of Medicine)

uriel pharmacy inc. - azadirachta indica flower (unii: 3te8a92upm) (azadirachta indica flower - unii:3te8a92upm), silver (unii: 3m4g523w1g) (silver - unii:3m4g523w1g), cupric cation (unii: 8cbv67279l) (cupric cation - unii:8cbv67279l), mercury (unii: fxs1by2pgl) (mercury - unii:fxs1by2pgl) - azadirachta indica flower 2 [hp_x] in 1 g - directions: for topical use only. use: temporary relief of athlete's foot.

Spojené štáty - angličtina - NLM (National Library of Medicine)

stellalife, inc. - azadirachta indica 1x apis mellifica 12x calendula 1x echinacea purpurea 1x okoubaka aubrevillei 6x phosphorous 12x plantago major 1 x strontium 30x thuja occidentalis 3x - azadirachta indica antigingivitis, swelling ■ antimicrobial and protective. ■ protects and hydrates oral cavity. ■ promotes oral health. ■ supports healthy gums. ■ freshens breath. ■ stop use and consult a healthcare professional if you experience irritation or unusual sensitivity, or develop a rash.

Európska únia - angličtina - EMA (European Medicines Agency)

csl behring gmbh - alpha1-proteinase inhibitor (human) - genetic diseases, inborn, lung diseases - antihemorrhagics, - respreeza is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes pizz, piz(null), pi(null,null), pisz). patients are to be under optimal pharmacologic and non-pharmacologic treatment and show evidence of progressive lung disease (e.g. lower forced expiratory volume per second (fev1) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency.,